Download Free Medical Intravenous Reolysin in Bone and Soft Tissue Sarcoma Metastatic to Lung PowerPoint Presentation

Intravenous Reolysin in Bone and Soft Tissue Sarcoma Metastatic to Lung PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Ewing Sarcoma, which is titled "Intravenous Reolysin in Bone and Soft Tissue Sarcoma Metastatic to Lung", to know about reovirus in a cell with non-activated Ras pathway.

Tags : Ewing Sarcoma, Intravenous Reolysin, Bone, Soft Tissue Sarcoma, Metastatic Lung

Published on : May 13, 2021 | Views : 1979 | Downloads : 0

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

INTRAVENOUS REOLYSIN IN BONE AND SOFT TISSUE SARCOMA METASTATIC TO LUNG M Mita, MD, MSc Clinical Investigator Assistant Professor of Medicine, IDD at CTRC/UTHSCSA San Antonio
Slide 2-

BACKGROUND Reolysin (reovirus serotype 3) Dearing strain, naturally occurring, ubiquitous, non-enveloped human reovirus Genome 10 segments of double-stranded RNA Community-acquired infection is mild and limited to the upper respiratory and GI tract. Virus replicates specifically in transformed cells possessing an activated Ras pathway.
Slide 3-

BACKGROUND The preferential lysis of cells with activated Ras pathway by reovirus appears to be due to the inhibition of double-stranded RNA-activated protein kinase (PKR) in these cells. In cells with Ras non-activated pathway, PKR autophosphorylates in the presence of viral transcripts, which activates it and results in inhibition of viral protein synthesis, thus preventing viral replication. In cells with activated RAS pathway the autophosphorylation of PKR is inhibited keeping it in an inactive state and allowing viral replication and eventually oncolysis.
Slide 4-

Reovirus in a cell with non-activated Ras pathway
Slide 5-

Reovirus growth in a cell with Ras activated pathway
Slide 6-

RATIONALE Sarcomas Rare tumors Very heterogeneous Incurable when metastatic, median survival 12 m. Available treatments are few with low RR and high toxicity There is an acute need for new drugs for treatment of sarcoma
Slide 7-

RATIONALE in vitro cytotoxicity assays in Ewing’s sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma cell lines revealed complete cell kill. (Kolb et al., AACR 2006) in vivo antitumor effect seen in xenograft models of pediatric sarcomas. (Ewing’s sarcoma and rhabdomyosarcoma). In all tumor lines evaluated, the reovirus exhibited significant antitumor activity, including a complete response in a rhabdomyosarcoma line. CONCLUSION: REOLYSIN demonstrated excellent anti-tumor activity in vitro and in vivo in sarcoma cell lines.
Slide 8-

PHASE II multi-institutional, open-label, single agent study designed to characterize the efficacy and safety of REOLYSIN given IV every 28 days in patients with bone and soft tissue sarcoma metastatic to lung.
Slide 9-

OBJECTIVES To measure tumor response and duration of response and describe any evidence of antitumor activity of intravenous multiple dose REOLYSIN in patients with bone and soft tissue sarcomas metastatic to the lung. To evaluate safety of intravenous multiple dose of REOLYSIN
Slide 10-

STUDY DESIGN IV infusion over 60 minutes days 1-5 REOLYSIN DOSE 3 X 1010 TCID50 Simon two-stage design 38 patients will be accrued to the first stage If 1 or more responses (prolonged SD > 6 months, partial or complete response) up to 52 patients will be accrued The agent will be considered active if 3 or more responses or prolonged SD are observed
Slide 11-

INCLUSION CRITERIA Pts with bone or soft tissue sarcoma metastatic to the lung unresponsive to, or untreatable by, standard therapies (histologies include osteosarcoma, Ewing sarcoma family tumors, malignant fibrous histiocytoma, synovial sarcoma, fibrosarcoma, and leiomyosarcoma). The patients must have no sites of active disease other than lungs unless agreed by the sponsor. Have 2 or more measurable metastatic lesions in the lungs detectable on CT scan. (RECIST) At least 16 years of age Have no continuing adverse effects from prior therapies; all such effects must have resolved to CTC AE version 3 ≤ grade 1
Slide 12-

INCLUSION CRITERIA Have received NO chemotherapy, radiotherapy, immunotherapy, hormonotherapy or surgery within 28 days prior to receiving REOLYSIN ECOG PS ≤ 2 Life expectancy of at least 3 months Laboratory results: ANC ≥ 1.5 X 109 Plats ≥ 100 X 109 HB ≥ 9.0 g/dl Creatinine ≤ 1.5 X ULN Bilirubin ≤ 1.5 X ULN AST/ALT ≤ ULN Negative pregnancy test for females of childbearing potential
Slide 13-

EXCLUSION CRITERIA Concurrent therapy with any other investigational anticancer agent while on study. Have inadequate pulmonary function defined as a forced expiratory volume in 1 second (FEV1) less than 50 % of predicted Be on immunosuppressive therapy; have known HIV infection or active hepatitis B or C Be a pregnant or breast feeding woman Have clinically significant pulmonary or cardiac disease including pre-existing arrhythmia, uncontrolled angina pectoris, myocardial infarction 1 year prior to study entry, or grade 2 or higher compromised LVEF Dementia or altered mental status Any severe, acute or chronic medical or psychiatric condition
Slide 14-

ENROLLMENT 35 patients Tumor types MFH 8 patients Synovial sarcoma 8 patients Osteosarcoma 6 patients Leiomyosarcoma 6 patients Undifferentiated round cell sarcoma 1 patient Ewing sarcoma 1 Liposarcoma 1 Rhabdomyosarcoma 1 Chordoma 1 High grade sarcoma 1 Alveolar sarcoma 1
Slide 15-

PATIENT CHARACTERISTICS Characteristics 35 patients Age 19-70 (median 51) Sex Female -16 patients Male -19 patients PS 0 -12 patients 1 - 23 patients
Slide 16-

PREVIOUS TREATMENTS Previous treatment lines for metastatic disease More than 3 lines: 11 patients 1-3 lines: 20 patients None: 4 patients Previous treatments Chemo only: 15 patients Chemo and XRT: 11 patients None: 4 patients Biological agents: 5 patients (sorafenib, mTOR inhibitors, bevacizumab)
Slide 17-

TOXICITIES (based on 25 patients enrolled at IDD) Constitutional grade 1 (fever, chills, fatigue, myalgias): 22 patients Respiratory grade 1 (cough, congestion): 14 patients Gastro-intestinal grade 1 (diarrhea): 10 patients Hematological: occurring during the week of treatment: Grade 2 ANC: 1 patient; Grade 3 ANC: 3 patients; grade 4 ANC-1 patient (1 day- C2D3, C3D3). Pt KS (received 16 cycles) grade 2-3 ANC during 13 cycles of treatment (day 3-4). No neutropenia over the last 3 cycles. Grade 2 thrombocytopenia – 2 patients Grade 1 anemia- 3 patients. Transaminitis: grade 2 AST/ALT – 1 patient (C1D8, C2D8, C3-5 D 5); grade 1 AST/ALT – 2 patients (C1D3 and C2D3) Palpitations: 2 patients (both with osteosarcoma, large lung mets). 1 patient had objective findings (arrythmia) received B blockers (etiology: possibly hypoxia).
Slide 18-

EFFICACY 1 patient (synovial sarcoma) SD after cycle 16 (ongoing). 1 patient Ewing sarcoma SD after 8 cycles (ongoing). 1 patient with osteosarcoma SD after 6 cycles (ongoing). 3 other patients SD after 4 cycles (leiomyosarcoma, chordoma, MFH). 15 patients SD after 2 cycles. 15 patients PD. No tumor reduction. 6/29 patients had SD > 16 weeks 21% 15/29 patients had SD for at least 8 weeks (2-16 months) 52% 4 patients are too early for evaluation; 2 patients came off study before tumor evaluation.
Slide 19-

ppt slide no 19 content not found
Slide 20-

ppt slide no 20 content not found
Slide 21-

CONCLUSION REOLYSIN PHASE II SARCOMA 35 patients enrolled to date Mild to moderate toxicities 2nd cycle better tolerated than 1st 3 patients SD for at least 6 months 21% patients SD >16 weeks 52% patients SD for at least 8 weeks
Slide 22-

CONCLUSION The study achieved the established objectives after the first 33 patients enrolled Enrollment will continue to 52 patients Future studies with Reolysin in combination with chemotherapy are planned in this patient population
Slide 23-

Acknowledgements IDD at CTRC/UTHSCSA: Tony Carmona, Alain Mita, John Sarantopoulos, Kamalesh Sankhala, Francis Giles Montefiore Medical Center: Sanjay Goel Mayo Clinic: Scott Okuno U Michigan Cancer Center: Rashmi Chugh Oncolytics: Karl Mettinger, Matt Coffey, Brad Thompson, Merle Kirkpatrick, Cathy Ward.
Slide 24-

THANK YOU
Slide 25-

The Institute for Drug Development A leader in anticancer drug development